Op-Ed: FTC Adds Fuel to the Fire for PBMs. Will Congress Deliver Real Reform?

Written by St. Paul Corner Drug (SPCD)

The FTC's reports and legal actions target PBMs for inflating drug costs and restricting access, focusing on insulin and specialty generics.

Read the article here
St. Paul Corner Drug (SPCD)
Previous

Lawmakers want Indiana to own its own pharmacy benefit manager for state plans like Medicaid
Next

Kansas pharmacists are closing their doors as they seek a way to save their businesses struggling from PBM practices